856 related articles for article (PubMed ID: 26920891)
21. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
22. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
23. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
24. Elevated blood levels of soluble tumor necrosis factor receptors in nasopharyngeal carcinoma: correlation with humoral immune response to lytic replication of Epstein-Barr virus.
Feng P; Chan SH; Ooi EE; Soo MY; Loh KS; Wang D; Ren EC; Hu H
Int J Oncol; 1999 Jul; 15(1):167-72. PubMed ID: 10375611
[TBL] [Abstract][Full Text] [Related]
25. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
Hutajulu SH; Ng N; Jati BR; Fachiroh J; Herdini C; Hariwiyanto B; Haryana SM; Middeldorp JM
J Med Virol; 2012 May; 84(5):768-76. PubMed ID: 22431025
[TBL] [Abstract][Full Text] [Related]
26. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
[TBL] [Abstract][Full Text] [Related]
27. Elevated Epstein-Barr virus seroreactivity among unaffected members of families with nasopharyngeal carcinoma.
Qin HD; Jia WH; Zhang LL; Liu N; Zhou XX; Wang MH; Feng QS; Chen LZ; Zhang Y; Jorgensen TJ; Zeng YX; Shugart YY
J Med Virol; 2011 Oct; 83(10):1792-8. PubMed ID: 21837797
[TBL] [Abstract][Full Text] [Related]
28. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
29. Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres.
Chen Y; Xu Y; Zhao W; Xiao X; Zhou X; Lin L; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
BMC Cancer; 2018 Feb; 18(1):190. PubMed ID: 29444646
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
[TBL] [Abstract][Full Text] [Related]
31. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.
Fachiroh J; Schouten T; Hariwiyanto B; Paramita DK; Harijadi A; Haryana SM; Ng MH; Middeldorp JM
J Infect Dis; 2004 Jul; 190(1):53-62. PubMed ID: 15195243
[TBL] [Abstract][Full Text] [Related]
32. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
[TBL] [Abstract][Full Text] [Related]
33. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients.
Ayadi W; Karray-Hakim H; Feki L; Khabir A; Boudawara T; Ghorbel A; Daoud J; Frikha M; Hammami A
J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836
[TBL] [Abstract][Full Text] [Related]
34. Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.
Gu AD; Lu LX; Xie YB; Chen LZ; Feng QS; Kang T; Jia WH; Zeng YX
J Transl Med; 2009 Aug; 7():73. PubMed ID: 19698162
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
36. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
37. Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma.
Paudel S; Warner BE; Wang R; Adams-Haduch J; Reznik AS; Dou J; Huang Y; Gao YT; Koh WP; Bäckerholm A; Yuan JM; Shair KHY
Clin Cancer Res; 2022 Dec; 28(23):5221-5230. PubMed ID: 36165913
[TBL] [Abstract][Full Text] [Related]
38. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
[TBL] [Abstract][Full Text] [Related]
39. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
40. Increasing the accuracy and scalability of the Immunofluorescence Assay for Epstein Barr Virus by inferring continuous titers from a single sample dilution.
Goh SM; Swaminathan M; Lai JU; Anwar A; Chan SH; Cheong I
J Immunol Methods; 2017 Jan; 440():35-40. PubMed ID: 27983956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
